Scheme

ITI Pharma and Healthcare Fund

Holds 37 companies worth ₹264 Cr in Sept 2026.

Fund house
ITIThe fund house that runs this scheme.
AUM
₹266 CrITI Pharma and Healthcare Fund's AUM at the end of 30 Sept 2026, as AMFI reports it. Down 3.7% on Aug 2026, ₹276 Cr.
Largest holding
Sun Pharmaceutical Ind LtdSun Pharmaceutical Ind Ltd is 12.0% of this scheme's NAV.
Fund manager
Nilay DalalRuns it since 8 May 2026, as the fund house dates it. With Animesh Singh (fund manager).

Holdings^{(Nov 2021 – Sept 2026)}

Holdings in Sept 2026. Tick up to 2 to plot them.
Plot	37 companies ·	₹ Cr
	Sun Pharmaceutical Ind Ltd	31.8
	Divi s Laboratories Limited	25.3
	Apollo Hospitals Enterprise Limited	14.5
	Dr Reddy s Laboratories Limited	12.7
	Torrent Pharmaceuticals Limited	12.7
	Max Healthcare Institute Limited	11.9
	Cipla	11.1
	Laurus Labs Limited	10.7
	Aurobindo Pharma	10.7
	Mankind Pharma Limited	10.1
	Cohance Lifesciences Limited	8.3
	Alkem Laboratories Limited	8.2
	Neuland Laboratories Limited	8.2
	Global Health Limited	7.6
	Fortis Healthcare Limited	7.4
	Abbott India Limited	5.7
	Lupin	5.4
	IPCA Laboratories Limited	5.2
	Sai Life Sciences Limited	5
	Shilpa Medicare Limited	4.3
	Aster DM Healthcare Limited	4.2
	Poly Medicure Limited	3.9
	Healthcare Global Enterprises Limited	3.9
	Piramal Pharma Limited	3.4
	Anthem Biosciences Limited	3.3
	Shaily Engineering Plastics Limited	3.2
	Glenmark Pharmaceuticals	3
	Gland Pharma Limited	2.7
	Supriya Lifescience Limited	2.7
	Rainbow Children s Medicare Limited	2.7
	GLAXO SMITHKLINE PHARMA	2.6
	BOC India Ltd	2.5
	Biocon	2.2
	Cadila Healthcare	2
	Metropolis Healthcare Limited	1.9
	Caplin Point Laboratories Limited	1.8
	Syngene International Limited	1.5

Sun Pharmaceutical Ind Ltd
Divi s Laboratories Limited

Market value of each ticked company in ITI Pharma and Healthcare Fund, ₹ crore. Month end. Source: AMC monthly portfolio disclosures.
Month	Sun Pharmaceutical Ind Ltd	Divi s Laboratories Limited
Sept 2025	₹24.1 Cr	₹17.6 Cr
Oct 2025	₹25.5 Cr	₹20.9 Cr
Nov 2025	₹29.4 Cr	₹20.2 Cr
Dec 2025	₹24.4 Cr	₹19.9 Cr
Jan 2026	₹22.6 Cr	₹18.9 Cr
Feb 2026	₹24.7 Cr	₹20 Cr
Mar 2026	₹24.9 Cr	₹18.5 Cr
Apr 2026	₹28.5 Cr	₹20.3 Cr
May 2026	₹33.9 Cr	₹20.1 Cr
Jun 2026	₹33.6 Cr	₹17.1 Cr
Jul 2026	₹34.9 Cr	₹20.9 Cr
Aug 2026	₹34.8 Cr	₹25.5 Cr
Sept 2026	₹31.8 Cr	₹25.3 Cr

Fig. 1.Market value of each ticked company in ITI Pharma and Healthcare Fund, ₹ crore. Month end. Source: AMC monthly portfolio disclosures.

Allocation^{(Sept 2026)}

Market cap

		% of NAV
Large Cap	5	35.89

Mid Cap	17	40.45

Small Cap	15	22.97

Cash & others		0.69

Sectors

Companies

Fig. 2.This scheme's holdings, by market cap, by sector and by company. Hover a slice or a row; click a slice to open it.

Buying and selling, month by month^{(Oct 2025 – Sept 2026)}

Buying and selling, month by month. Change in market value since the previous month, ₹ crore. Month end. Source: AMC monthly portfolio disclosures.

Fig. 3.Change in market value since the previous month, ₹ crore. Month end. Source: AMC monthly portfolio disclosures.

Portfolio^{(Sept 2026)}

Every holding in Sept 2026: its shares, market value (₹ crore) and % of NAV. Month end. Source: AMC monthly portfolio disclosures. Click a column's header to sort by it.

Sun Pharmaceutical Ind Ltd	Equity	Pharmaceuticals & Biotechnology	1.75L	31.8	11.96
Divi s Laboratories Limited	Equity	Pharmaceuticals & Biotechnology	27.2K	25.3	9.51
Apollo Hospitals Enterprise Limited	Equity	Healthcare Services	17.7K	14.5	5.45
Dr Reddy s Laboratories Limited	Equity	Pharmaceuticals & Biotechnology	1.03L	12.7	4.78
Torrent Pharmaceuticals Limited	Equity	Pharmaceuticals & Biotechnology	26.5K	12.7	4.78
Max Healthcare Institute Limited	Equity	Healthcare Services	1.28L	11.9	4.49
Cipla	Equity	Pharmaceuticals & Biotechnology	82.8K	11.1	4.19
Laurus Labs Limited	Equity	Pharmaceuticals & Biotechnology	54K	10.7	4.02
Aurobindo Pharma	Equity	Pharmaceuticals & Biotechnology	63.9K	10.7	4.01
Mankind Pharma Limited	Equity	Pharmaceuticals & Biotechnology	40.1K	10.1	3.78
Cohance Lifesciences Limited	Equity	Pharmaceuticals & Biotechnology	1.88L	8.3	3.14
Alkem Laboratories Limited	Equity	Pharmaceuticals & Biotechnology	15.9K	8.2	3.09
Neuland Laboratories Limited	Equity	Pharmaceuticals & Biotechnology	3.82K	8.2	3.07
Global Health Limited	Equity	Healthcare Services	55.6K	7.6	2.85
Fortis Healthcare Limited	Equity	Healthcare Services	95.8K	7.4	2.77
Abbott India Limited	Equity	Pharmaceuticals & Biotechnology	2.1K	5.7	2.14
Lupin	Equity	Pharmaceuticals & Biotechnology	26.8K	5.4	2.04
IPCA Laboratories Limited	Equity	Pharmaceuticals & Biotechnology	26.8K	5.2	1.94
Sai Life Sciences Limited	Equity	Pharmaceuticals & Biotechnology	32.6K	5	1.87
Shilpa Medicare Limited	Equity	Pharmaceuticals & Biotechnology	41K	4.3	1.61
Aster DM Healthcare Limited	Equity	Healthcare Services	60.9K	4.2	1.59
Poly Medicure Limited	Equity	Healthcare Equipment & Supplies	23.5K	3.9	1.48
Healthcare Global Enterprises Limited	Equity	Healthcare Services	58.5K	3.9	1.47
Piramal Pharma Limited	Equity	Pharmaceuticals & Biotechnology	1.64L	3.4	1.27
Anthem Biosciences Limited	Equity	Pharmaceuticals & Biotechnology	38.6K	3.3	1.25
Shaily Engineering Plastics Limited	Equity	Consumer Durables	10.6K	3.2	1.22
Glenmark Pharmaceuticals	Equity	Pharmaceuticals & Biotechnology	12.8K	3	1.13
Gland Pharma Limited	Equity	Pharmaceuticals & Biotechnology	9.44K	2.7	1.03
Supriya Lifescience Limited	Equity	Pharmaceuticals & Biotechnology	28K	2.7	1.00
Rainbow Children s Medicare Limited	Equity	Healthcare Services	20.1K	2.7	1.00
GLAXO SMITHKLINE PHARMA	Equity	Pharmaceuticals & Biotechnology	9.21K	2.6	0.96
BOC India Ltd	Equity	Chemicals & Petrochemicals	3.87K	2.5	0.92
Biocon	Equity	Pharmaceuticals & Biotechnology	58.5K	2.2	0.81
Cadila Healthcare	Equity	Pharmaceuticals & Biotechnology	16.8K	2	0.73
Metropolis Healthcare Limited	Equity	Healthcare Services	34.9K	1.9	0.71
Caplin Point Laboratories Limited	Equity	Pharmaceuticals & Biotechnology	6.7K	1.8	0.68
Syngene International Limited	Equity	Healthcare Services	41.3K	1.5	0.57

Fig. 4.Every holding in Sept 2026: its shares, market value (₹ crore) and % of NAV. Month end. Source: AMC monthly portfolio disclosures.